NASDAQ:BBOT BridgeBio Oncology Therapeutics (BBOT) Stock Price, News & Analysis $2.02 -0.12 (-5.37%) As of 11:29 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOwnershipSEC FilingsShort Interest About BridgeBio Oncology Therapeutics Stock (NASDAQ:BBOT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BBOT alerts:Sign Up Key Stats Today's Range$2.00▼$2.2350-Day Range$2.04▼$8.9852-Week Range$1.98▼$14.87Volume260,944 shsAverage Volume433,338 shsMarket Capitalization$162.51 millionP/E RatioN/ADividend YieldN/APrice Target$19.33Consensus RatingModerate Buy Company Overview BridgeBio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted treatments for cancers driven by RAS and related signaling pathways. The company’s research centers on disrupting molecular signals that help cancer cells grow and survive. Its development programs include drug candidates designed to target KRAS mutations and interactions between RAS and other cancer-related proteins. These investigational medicines are being studied for potential use in solid tumors; they are not approved treatments. BridgeBio Oncology Therapeutics emerged from BridgeBio Pharma’s oncology business. Its work includes drug development and clinical research, with programs aimed at addressing cancers for which existing targeted treatment options remain limited.AI Generated. May Contain Errors. Read More BridgeBio Oncology Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks76th Percentile Overall ScoreBBOT MarketRank™: 3.81657590649 of 5 starsBridgeBio Oncology Therapeutics scored higher than 76% of companies evaluated by MarketBeat, and ranked 122nd out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingBridgeBio Oncology Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on no strong buy ratings, 10 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialBridgeBio Oncology Therapeutics has a consensus price target of $19.33, representing about 803.4% upside from its current price of $2.14.Amount of Analyst CoverageBridgeBio Oncology Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BridgeBio Oncology Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for BridgeBio Oncology Therapeutics are expected to grow in the coming year, from ($2.75) to ($2.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BridgeBio Oncology Therapeutics is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BridgeBio Oncology Therapeutics is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBridgeBio Oncology Therapeutics has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.72% of the float of BridgeBio Oncology Therapeutics has been sold short.Short Interest Ratio / Days to CoverBridgeBio Oncology Therapeutics has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in BridgeBio Oncology Therapeutics has recently decreased by 9.82%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBridgeBio Oncology Therapeutics does not currently pay a dividend.Dividend GrowthBridgeBio Oncology Therapeutics does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.46 News SentimentBridgeBio Oncology Therapeutics has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for BridgeBio Oncology Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for BBOT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added BridgeBio Oncology Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BridgeBio Oncology Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders24.40% of the stock of BridgeBio Oncology Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions54.89% of the stock of BridgeBio Oncology Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BridgeBio Oncology Therapeutics' insider trading history. Receive BBOT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BridgeBio Oncology Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BBOT Stock News HeadlinesBridgeBio Oncology Therapeutics (NASDAQ:BBOT) Stock Gets Price Target Reduction from WedbushNovember 14 at 2:54 AM | americanbankingnews.comBridgeBio Oncology Therapeutics (NASDAQ:BBOT) Stock Moved Up to Hold by Wall Street ZenNovember 14 at 1:54 AM | americanbankingnews.comMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment that covers a full year, with no subscription and no re-bills. Every night after the close, the scanner screens nearly a thousand of America's biggest stocks. It returns a short list of qualifying setups with the exact buy price next to each one. There's nothing to install. If you decide it's not for you, you get the $7 back and keep the scanner for the year.November 16 at 1:00 AM | Profits Run (Ad)BBOT Reports Third Quarter 2026 Financial Results and Update on Corporate ProgressNovember 10, 2026 | globenewswire.comPiper Sandler Remains a Buy on BridgeBio Oncology Therapeutics (BBOT)October 27, 2026 | theglobeandmail.comBridgeBio Oncology: The KRAS Opportunity Hidden In The SelloffOctober 19, 2026 | seekingalpha.comBridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)October 12, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: CVS Health (CVS), Ascendis Pharma (ASND) and BridgeBio Oncology Therapeutics (BBOT)September 16, 2026 | theglobeandmail.comSee More Headlines BBOT Stock Analysis - Frequently Asked Questions How have BBOT shares performed this year? BridgeBio Oncology Therapeutics' stock was trading at $11.50 on January 1st, 2026. Since then, BBOT shares have decreased by 81.4% and is now trading at $2.14. How were BridgeBio Oncology Therapeutics' earnings last quarter? BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) released its quarterly earnings data on Tuesday, November, 10th. The company reported ($0.43) earnings per share for the quarter, beating analysts' consensus estimates of ($0.65) by $0.22. Who are BridgeBio Oncology Therapeutics' major shareholders? BridgeBio Oncology Therapeutics' top institutional investors include Regents of The University of California (3.13%), State Street Corp (1.11%), Marshall Wace LLP (0.60%) and Palumbo Wealth Management LLC (0.12%). How do I buy shares of BridgeBio Oncology Therapeutics? Shares of BBOT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/10/2026Today11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 BBOT's financial health is in the Red zone, according to TradeSmith. BBOT has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BBOT CIK1869105 Webwww.bridgebio.com Phone(857) 702-0377FaxN/AEmployees88Year Founded2025Price Target and Rating Average Price Target for BridgeBio Oncology Therapeutics$19.33 High Price Target$29.00 Low Price Target$9.00 Potential Upside/Downside+852.4%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($2.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$134.04 million Net MarginsN/A Pretax MarginN/A Return on Equity-49.01% Return on Assets-43.18% Debt Debt-to-Equity RatioN/A Current Ratio4.08 Quick Ratio4.08 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.14 per share Price / Book0.39Miscellaneous Outstanding Shares80,251,000Free Float60,670,000Market Cap$162.91 million OptionableN/A Beta0.86 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:BBOT) was last updated on 11/16/2026 by MarketBeat.com Staff. From Our PartnersMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment t...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredThis Could Be the Biggest Monetary Shift in 50 YearsThe U.S. government still values its gold reserves at $42 an ounce, a price set by Congress in 1973. Gold trad...Patriot Gold Group | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredBeginner’s Guide to GoldThe Ultimate Beginner's Guide to Gold IRAs Protect Your Retirement Savings Before It's Too Late With This I...Goldco Direct, LLC | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BridgeBio Oncology Therapeutics, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share BridgeBio Oncology Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.